Stevanato Group SpA

Stevanato Group’s insider filings show key executives keep their major stakes, signaling confidence in the company’s biopharma packaging strategy and potential upside as demand for prefilled syringes rises.

Stevanato Group insiders keep their positions steady while RSUs unlock in 2024‑2027, signaling confidence in growing prefilled syringe demand and potential future price moves.

Stevanato Group insider buys 119,700 shares at $15.35, reflecting confidence in its prefilled‑syringe growth strategy while keeping volatility low.